MedPath

Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression

Phase 4
Completed
Conditions
Normal Healthy Subject Population
Interventions
Registration Number
NCT00808769
Lead Sponsor
Procter and Gamble
Brief Summary

The purpose of this study is to compare Prilosec OTC® and Zegerid® in their effects on gastric acid suppression.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Normal subjects who are 18-65 years of age;
  • Non-childbearing potential females or those using birth control
Exclusion Criteria
  • History of significant GI disease
  • Any significant medical illness
  • History of hypersensitivity, allergy or intolerance to omeprazole or other proton pump inhibitors;
  • Currently using GI medications
  • GI disorder or surgery leading to impaired drug absorption

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
1Zegerid®Zegerid®
2Prilosec OTC®Prilosec OTC®
Primary Outcome Measures
NameTimeMethod
The Mean Percent Time Gastric pH > 4.0 on Day 1continuously over a 24 hour period

In this study, there was evidence of gastric pH probe failure and a high incidence of biologically improbable pH measurements (sustained pH \< 1.0) that bring the validity of the results into question. The results of this study are, therefore, inconclusive.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Research Site

🇺🇸

Oklahoma City, Oklahoma, United States

Research Site
🇺🇸Oklahoma City, Oklahoma, United States
© Copyright 2025. All Rights Reserved by MedPath